Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis

Table 1

Characteristics of studies included in the meta-analysis.

First author	Year	Number of patients	Mean age	Stage	Method	Clone number of antibodies	Dilution	c-Met expression (%)	Definition negative	Time to collect cases (year)
Baykal [22]	2003	94	45	I 1B	IHC	Santa Cruz	NR	56/94 (59.6%)	≤25%	1980–1994
Tsai [23]	2006	69	50	I A, I B/II A, and II B	IHC	Santa Cruz	1 : 200	21/69 (30, 4%, ACA)	<10%	1990–2003
Shu [24]	2008	50	NR	I/II	IHC	Zhongshan Beijing Biological Technology Co. Ltd.	NR	31/50 (62.0%)	Nonstaining	2005–2007
Wu [25]	2009	48	49.6	I, II/III, and IV	IHC	Zhongshan Beijing Biological Technology Co. Ltd.	NR	42/48 (87.5%)	Nonstaining	2001–2005
Wang [26]	2010	48	47	II A	IHC	Boster (Wu Han)	NR	35/48 (73.0%)	<1 score	2007-2008
Zhang [27]	2010	71	47	I, II/III, and IV	IHC	Boster (Wu Han)	NR	37/71 (52.1%)	≤1 score	2007.4–2008.2
Kim [28]	2013	179	43.8	I, II/IV	IHC	Abcam	1 : 500	152/179	0 scores	1996–2010
Yin [29]	2013	35	NR	NR	IHC	ZSGB-BIO	NR	18/35 (51.43%)	≤10%	2009.12–2010.8
Zhou [30]	2014	91	43.694 ± 8.714	I/II	IHC	Bioss (Beijing)	1 : 200	73/91 (80.2%)	0%	2010.4–2012.11

Positive-staining cells: staining cell score × positive cell percentage = total score; nonstaining cells: no cell staining; proportion of staining cells: 0, 10%, and 25%; IHC: immunocytochemistry.